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MaBACKGROUND Recent coronary stent placement and noncardiac surgery contribute to the risk of adverse cardiac
events, but the relative contributions of these two factors have not been quantiﬁed.
OBJECTIVES This research was designed to determine the incremental risk of noncardiac surgery on myocardial
infarction (MI) and coronary revascularization following coronary stenting.
METHODS A U.S. retrospective cohort study of patients receiving coronary stents at Veterans Affairs medical centers
between 2000 and 2010 was used to match patients undergoing noncardiac surgery within 24 months of stent place-
ment to two patients with stents not undergoing surgery. Patients were matched on stent type and cardiac risk factors
present at the time of stent placement. A composite endpoint of MI and/or cardiac revascularization for the 30-day
interval post-surgery was calculated. Adjusted risk differences (RD) were compared across time periods following stent
implantation, using generalized estimating equations.
RESULTS We matched 20,590 surgical patients to 41,180 nonsurgical patients. During the 30-day interval following
noncardiac surgery, the surgical cohort had higher rates of the composite cardiac endpoint (3.1% vs. 1.9%; RD: 1.3%;
95% conﬁdence interval: 1.0% to 1.5%). The incremental risk of noncardiac surgery adjusted for surgical characteristics
ranged from 3.5% immediately following stent implantation to 1% at 6 months, after which it remained stable out to
24 months. Factors associated with a signiﬁcant reduction in risk following surgery more than 6 months post-stent
included elective inpatient procedures (DRD: 1.8%; p ¼ 0.01), high-risk surgery (DRD: 3.7%; p ¼ 0.01), and drug-eluting
stent (DES) (DRD: 1.3%; p ¼ 0.01).
CONCLUSIONS The incremental risk of noncardiac surgery on adverse cardiac events among post-stent patients is
highest in the initial 6 months following stent implantation and stabilizes at 1.0% after 6 months. Elective, high-risk,
inpatient surgery, and patients with DES may beneﬁt most from delay from a 6-month delay after stent
placement. (J Am Coll Cardiol 2014;64:2730–9) © 2014 by the American College of Cardiology Foundation.T he prevalence of surgical intervention withinthe 2 years following coronary stent implan-tation in the U.S. is estimated between 12%
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AB BR E V I A T I O N S
AND ACRONYM S
BMS = bare-metal stent(s)
DES = drug-eluting stent(s)
MI = myocardial infarction
RCRI = revised Cardiac
Risk Index
RD = risk difference
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2731response to surgery. Important cardiac drivers of
adverse event risk include a history of ischemic heart
disease, congestive heart failure, and the time be-
tween coronary stent implantation and the surgery
(2,8,9), while surgical factors implicated include ur-
gency and complexity of the surgical procedure (4).
However, the relative contribution of these cardiac
and surgical factors to overall postoperative risk,
and whether risk changes over time following stent-
ing, are currently unknown. Understanding these
contributions to risk would allow for more tailored,
effective mitigation strategies, such as antiplatelet
and statin therapies to minimize exacerbations of car-
diac disease, as well as stable hemodynamic control
and postoperative analgesia to minimize the stress
of surgery (10). Additionally, the knowledge of which
surgical characteristics are associated with the high-
est risk, especially in the early post-stent period,
would improve pre-operative risk assessment and
perioperative anesthesia management.SEE PAGE 2740To estimate the relative contributions of surgical
and cardiac factors to perioperative adverse cardiac
events, we compared event rates in a cohort of post-
stent patients undergoing noncardiac surgery to
those in a matched cohort of post-stent patients not
undergoing surgery to determine the incremental
effect of surgery on perioperative events. In addition,
we conducted analyses exploring the effect of time
between coronary stent implantation and surgery on
postoperative cardiac events and determined how
this risk differs by surgical procedure type.
METHODS
STUDY DESIGN AND DATA SOURCES. Weperformeda
matched retrospective cohort study to assess the incre-
mental risk of surgery on postoperative adverse cardiac
events following coronary stent implantation. Patients
with a coronary stent implanted at Veterans Affairs (VA)
medical centers betweenOctober 1, 1999, and September
30, 2009, were identiﬁed in the VA Patient Treatment
Files by International Classiﬁcation of Diseases-Ninth
Edition (ICD-9) procedure codes of 36.06 for bare-metal
stent (BMS) or 36.07 for drug-eluting stent (DES).
Following the identiﬁcation of the study cohort, infor-
mation on noncardiac procedures in the 24 months
following coronary stent implantation was obtained
from the VA National Surgery Ofﬁce and the Centers for
Medicaid & Medicare Services. Noncardiac surgery was
deﬁned by CPT codes, and detailed information on the
construction of the study cohort and study variables has
been previously published (4). Admission status wasdeﬁned as elective if a patient was admitted to
the hospital from home, and all other admission
sources were considered nonelective.
STUDY POPULATION. We compared all pa-
tients with coronary stents undergoing
noncardiac surgery in the 24months following
stent implantation to patients with coronary
stents not undergoing subsequent surgery.
Each patient undergoing surgery wasmatched
to two patients who did not undergo surgery.Matching
was on the basis of patient age, race, stent type (BMS or
DES), year of stent placement, each of the six variables
included in the revised Cardiac Risk Index (RCRI) (9),
and those identiﬁed in our previous analyses as sig-
niﬁcant predictors of major adverse cardiac events,
including myocardial infarction (MI) 6 months prior to
stent implantation and peripheral vascular disease (4).
Patients in the nonsurgical cohort were required to be
alive during the time interval following stent place-
ment when their matched counterpart underwent
surgery. That is, if a surgical patient had surgery 200
days following stent placement, their two matched
nonsurgical patients had to be alive for at least 200
days following their stent placements.
OUTCOME VARIABLES. Our primary outcome was a
composite endpoint of acute MI and/or coronary
revascularization by percutaneous coronary inter-
vention or coronary artery bypass grafting within
30 days following surgery in the surgical cohort or the
equivalent post-stent time period for the nonsurgical
cohort. We did not include all-cause mortality in our
composite endpoint as the cohorts were not matched
on probability of death at the time of stent placement.
We excluded patients from the study who underwent
surgery within 2 weeks following coronary stent
placement as it was difﬁcult to attribute an MI to
surgery versus an MI associated with receiving a
coronary stent on the basis of administrative data.
ANALYTICALMETHODS. Assessment of the matched
cohort . The matched cohort was compared by uni-
variate and bivariate frequencies to describe patient
characteristics and the composite outcome of adverse
cardiac events. Bivariate frequencies were compared
using chi-square tests and continuous variables were
compared using Wilcoxon rank-sum tests. To ensure
effective matching on cardiac event outcomes, we cal-
culated the cumulative risk of the composite cardiac
endpoint using Kaplan-Meier survival curves comparing
time to ﬁrst outcome by cohort and by stent type.
Assessment of the incremental risk of noncardiac
surgery. To determine the incremental risk of surgery
on adverse cardiac events, we estimated the risk
difference for adverse events in the 30 days following
TABLE 1 Characteris
Type of stent
DES
BMS
Demographics at time
Age, yrs
Race
White
Black
Other
Sex
Male
Female
Comorbidities at time o
Matched
MI in past 6 mont
Diabetes in past 2
PVD in past 2 yrs
CHF in past 2 yrs
CVD in past 2 yrs
Unmatched
Hypertension in th
Hyperlipidemia in
Obesity
Smoking
Stent indication
Acute coronary syn
Elective
Fiscal year of stent pla
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
Values are n (%) or median
BMS ¼ bare-metal sten
vascular disease; MI ¼ myo
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2732procedure by calculating the rate for the nonsurgical
patients during the same 30-day time interval
following stent as their matched surgery. For
example, in a nonsurgical cohort patient matched to a
surgical cohort patient at 370 days post-stent, we only
examined adverse cardiac events during the time
period of 370 to 400 days post-stent. Unadjusted risk
differences and 95% conﬁdence intervals (CI) for
all outcomes were determined both overall and
stratiﬁed by time since coronary stent placement us-
ing binomial regression models and incorporating
generalized estimating equations (GEE).tics of the Study Population
Stent/Surgery
(n ¼ 20,590)
Stent Only
(n ¼ 41,180) p Value
1.00
11,110 (54.0) 22,220 (54.0)
9,480 (46.0) 18,960 (46.0)
of stent placement
63 (58–70) 63 (58–70) 0.53
1.00
19,075 (93.7) 38,150 (93.7)
1,189 (5.8) 2,378 (5.8)
83 (0.4) 166 (0.4)
0.02
20,228 (98.2) 40,560 (98.5)
362 (1.8) 620 (1.5)
f stent placement
hs 7,442 (36.1) 14,884 (36.1) 1.00
yrs 9,093 (44.2) 18,186 (44.2) 1.00
4,127 (20.0) 8,254 (20.0) 1.00
4,576 (22.2) 9,152 (22.2) 1.00
494 (2.4) 988 (2.4) 1.00
e past year 17,855 (86.7) 35,383 (85.9) 0.01
the past year 16,843 (81.8) 34,189 (83.0) <0.001
4,832 (23.5) 9,532 (23.2) 0.37
7,900 (38.4) 15,737 (38.2) 0.71
<0.001
drome 13,612 (66.1) 28,269 (68.6)
6,978 (33.9) 12,911 (31.4)
cement 1.00
1,161 (5.6) 2,322 (5.6)
1,423 (6.9) 2,846 (6.9)
1,570 (7.6) 3,140 (7.6)
1,691 (8.2) 3,382 (8.2)
1,961 (9.5) 3,922 (9.5)
2,234 (10.8) 4,468 (10.8)
2,310 (11.2) 4,620 (11.2)
2,166 (10.5) 4,332 (10.5)
2,341 (11.4) 4,682 (11.4)
2,039 (9.9) 4,078 (9.9)
1,694 (8.2) 3,388 (8.2)
(interquartile range).
t(s); CHF ¼ congestive heart failure; DES ¼ drug-eluting stent(s); CVD ¼ cerebro-
cardial infarction; PVD ¼ peripheral vascular disease.Contr ibut ion of t ime post-s tent to incrementa l
r i sk of surgery . We sought to determine how sur-
gical risk for adverse cardiac events changes over
time since stent placement. Examination of unad-
justed plots strongly suggested that the relationship
between cardiac risk and time from stent is nonlinear.
To fully understand this, we considered time as a
continuous variable in the main analyses. Additional
analyses considered timing intervals to simplify
clinical interpretation.
To plot changes in risk difference across time as a
continuous variable, adjusted risk differences for
adverse cardiac events were ﬁrst determined by
calculating a baseline risk of events across time since
stent using a generalized additive model. Covariates
in the baseline risk model included history of
ischemic heart disease, congestive heart failure, ce-
rebral vascular disease, chronic kidney disease, and
insulin-dependent diabetes mellitus. Next, the pre-
dicted probability of adverse cardiac events for each
surgical patient was calculated using a second
generalized additive model that adjusted for surgery
type, surgery admission status, and work relative
value unit as a measure of surgical complexity. The
ﬁnal adjusted risk difference for each surgical case
was determined by taking the difference between the
baseline risk of the matched nonsurgical patient and
the predicted probability of adverse cardiac events
following surgery for the surgical patient.
Changes in inc rementa l r i sk of surgery by t ime
interva ls . To test whether speciﬁc factors contrib-
uted to the reduction in risk by time intervals, we used
an interaction termwithin the GEEmodel to determine
signiﬁcant changes in risk difference by stent type,
procedure type, surgical complexity, and case status
across time of coronary stent placement (<6 weeks,
6 weeks to 6 months, and >6 months). Bivariate fre-
quencies and GEE models were completed using SAS
version 9.2 (SAS Institute Inc., Cary, North Carolina).
Adjusted risk differences were calculated and plotted
using R packages MGCV and GGPLOT (11,12).
RESULTS
MATCHED VARIABLES AND CHARACTERISTICS OF
THE SURGICAL AND NONSURGICAL COHORTS. Of
41,989 surgeries, we matched 49% to two patients in
the nonsurgical cohort on the basis of stent type and
cardiac risk factors. Differences between the matched
and nonmatched surgeries are presented in Online
Table 1. On the basis of available VA Clinical
Assessment, Reporting, and Tracking Program infor-
mation, the majority of stents in both cohorts during
the study period were ﬁrst-generation DES (58.0%),
TABLE 2 Characteristics of Surgical Procedures in the
Matched Surgical Cohort (N ¼ 20,590)
Surgery type
Integumentary 3,538 (17.2)
Genital/urinary 3,396 (16.5)
Eye/ear 3,379 (16.4)
Musculoskeletal 3,151 (15.3)
Digestive 2,503 (12.2)
Vascular 1,985 (9.6)
Nervous 1,245 (6.0)
Respiratory 1,109 (5.4)
Other* 284 (1.4)
High risk?
Yes 1,974 (9.6)
No 18,616 (90.4)
Location
VA facility 14,925 (72.5)
CMS facility 5,665 (27.5)
Admission status
Outpatient 13,246 (64.3)
Elective inpatient 6,637 (32.2)
Nonelective inpatient 707 (3.4)
Surgical complexity
<10 RVU 12,441 (60.4)
10–20 RVU 6,032 (29.3)
>20 RVU 2,115 (10.3)
Time since stent placement
<6 weeks 1,125 (5.5)
6 weeks to <3 months 2,112 (10.3)
3–<12 months 8,055 (39.1)
12–24 months 9,298 (45.2)
Timing of surgery†
Pre-guidelines (FY2000–FY2007) 12,296 (59.7)
Post-guidelines (FY2008–FY2011) 8,294 (40.3)
Values are n (%) of overall study population (N ¼ 61,770). *Includes
primary CPT codes of General (1000–10039), Hemic and Lymphatic
(38100–39999), and Endocrine (60000–60999) operations. †American College
of Cardiology/American Heart Association guidelines were published in October
of 2007.
CMS ¼ Centers for Medicaid & Medicare Services; FY ¼ ﬁscal year; RVU ¼
relative value unit; VA ¼ Veterans Affairs.
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2733with 58.4% sirolimus-eluting and 42.9% paclitaxel-
eluting in the surgical cohort versus 55.9% and
44.8% in the nonsurgical cohort, respectively (Online
Table 2). Demographics and comorbidities of the sur-
gical and nonsurgical cohort after matching are pre-
sented in Table 1. Approximately two-thirds of stents
in both cohorts were placed for acute coronary syn-
dromes. The surgical cohort had higher rates of elec-
tive stent placement compared with the nonsurgical
cohort (33.9% vs. 31.4%). The matched surgical pro-
cedures included a broad representation of surgical
procedure types and most surgeries were performed
at a VA hospital (Table 2). To examine secular trends
and evolving stent technology over the study period,
we determined the rates of the composite cardiac
endpoint by the ﬁscal year of stent placement (Online
Figure 1). Postoperative adverse cardiac event rates
remained relatively stable over time for both surgical
and nonsurgical cohorts and by stent type. The
cumulative incidence of adverse cardiac events over
the 24 months following coronary stent placement
was similar in both the surgical and nonsurgical co-
horts when stratiﬁed by stent type indicating that
both cohorts were evenly matched on risk for adverse
cardiac events (Figure 1). When stratiﬁed by stent
type, the surgical cohort had lower adverse cardiac
event rates compared to the nonsurgical cohort fol-
lowing BMS placement (18.6% vs. 19.0%) but higher
rates were observed with DES (16.2% vs. 15.1%) over
the 24-month time period.
THIRTY-DAY POST-SURGICAL OUTCOMES OF THE
SURGICAL COHORT COMPARED TO NONSURGICAL
COHORT. To better reﬁne the incremental risk asso-
ciated with surgery, we restricted the comparison to
adverse cardiac events occurring in the 30-day interval
following surgery for the surgical cohort and the same
post-stent period for the matched nonsurgical cohort.
We observed higher rates of the composite cardiac
endpoint (3.1% vs. 1.9%), MI (2.5% vs. 1.1%), and all-
cause mortality (1.4% vs. 0.4%) (all p <0.001) in the
surgical population compared with those who did not
undergo surgery. There was no difference in revascu-
larization rates (1.1% vs. 1.0%; p ¼ 0.37). The RD for the
surgical cohort during the 30-day period following
surgery for MIwas 1.4% (95% CI: 1.2% to 1.7%) and 1.0%
(95% CI: 0.9% to 1.2%) for all-cause mortality
compared to the nonsurgical cohort (Table 3).
INCREMENTAL RISK OF NONCARDIAC SURGERY
FOR ADVERSE CARDIAC EVENTS ACROSS TIME
FROM CORONARY STENT. The 30-day adverse
cardiac event rates for both the surgical cohort
and nonsurgical cohorts decrease over time as time
from stent placement increases (Figure 2A). Ratesfor both cohorts were highest immediately post-stent
and decreased rapidly in the ﬁrst 6 months regardless
of stent type. The risk difference, adjusted for
surgical characteristics associated with adverse
cardiac events, is plotted in Figure 2B. The adjusted
risk difference is highest in the ﬁrst 6 weeks
following stent implantation, decreasing sharply
in the ﬁrst 6 months, and leveling off to 1%
for the remainder of the 24 months. This pattern
is similar for surgery following DES or BMS
implantation.
INCREMENTAL RISK OF NONCARDIAC SURGERY
STRATIFIED BY <6 WEEKS, 6 WEEKS TO 6 MONTHS,
AND >6 MONTHS. To quantify the incremental risk
of surgery over time following stent placement, we
TABLE 3 Adverse Ca
Time Interval: Surgica
Event
A
(
Composite cardiac*
MI
Revascularization
All-cause mortality
Values are n (%) unless ot
bypass grafting or coronar
MI ¼ myocardial infarcti
FIGURE 1 Cumulative Incidence of Adverse Cardiac Events Following
Coronary Stent Placement
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The cumulative incidence of adverse cardiac events (includes myocardial infarction and/or
revascularization) over 24 months from time of coronary stent placement. Results are
stratiﬁed by surgical versus nonsurgical cohort and by stent type. BMS ¼ bare-metal
stent(s); DES ¼ drug-eluting stent(s).
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2734stratiﬁed 30-day adverse cardiac events post-
procedure into three time intervals of <6 weeks,
6 weeks to 6 months, and >6 months from time of
stent placement (Table 4). When surgeries were per-
formed in the ﬁrst 6 weeks following stent place-
ment, the overall rates and associated RDs of the
composite cardiac endpoint (9.0%; RD: 2.8%; 95% CI:
0.8% to 4.8%), MI (7.5%; RD: 3.6%; 95% CI: 1.8% to
5.4%), and death (3.2%; RD: 2.5%; 95% CI: 1.4% to
3.6%)weremarkedly higher compared to the later time
intervals. Across the three time intervals, a decreasing
trend in the rates and associated RDs was observed
for all of the adverse event endpoints, excepting
revascularization.
EVALUATION OF PROCEDURE CHARACTERISTICS
ASSOCIATED WITH REDUCED INCREMENTAL RISK
FOR SURGERY >6 MONTHS POST-STENTING. Given
that the risk for adverse cardiac events associatedrdiac Events and All-Cause Mortality at 30 Days Post-Operative
l Versus Nonsurgical Cohort
ll Patients
N ¼ 61,770)
Stent/Surgery
(n ¼ 20,590)
Stent Only
(n ¼ 41,180) p Value
Overall Risk
Difference, %
(95% CI)
1,414 (2.3) 643 (3.1) 771 (1.9) <0.001 1.3 (1.0 to 1.5)
981 (1.6) 521 (2.5) 460 (1.1) <0.001 1.4 (1.2 to 1.7)
631 (1.0) 221 (1.1) 410 (1.0) 0.37 0.1 (-0.1 to 0.3)
450 (0.7) 292 (1.4) 158 (0.4) <0.001 1.0 (0.9 to 1.2)
herwise noted. *Postoperative acute MI and/or revascularization with coronary artery
y stent placement.
on.with surgery was stabilized at 6 months from stent
placement, we sought to determine which procedure
types would most beneﬁt from delaying surgery until
6 months after stent deployment. Accordingly, we
compared the RD between two different stent to sur-
gery time periods: 6 weeks to 6 months and 6 months
to 24 months following stent placement. Non-
elective surgeries (RD6wk–6mo: 12.3%; RD6mo–24mo:
7.6%), vascular (RD6wk–6mo: 3.8%; RD6mo-24mo: 2.7%),
and respiratory (RD6wk–6mo: 3.0%; RD6mo–24mo: 3.3%)
procedures confer the highest RD for adverse cardiac
events, but risk was not signiﬁcantly decreased
between the two time periods (Table 5). Compared to
earlier surgery, digestive procedures (RD6wk–6mo:
4.6%; RD6mo–24mo: 0.9% [p ¼ 0.003]), high-risk
surgeries (RD6wk–6mo: 6.5%; RD6mo–24mo: 2.1% [p ¼
0.01]), and elective inpatient cases (RD6wk–6mo: 3.7%;
RD6mo–24mo: 1.9% [p ¼ 0.01]) are associated with a
signiﬁcant decrease in the RD when performed more
than 6 months following stent. Surgery performed on
patients with a DES more than 6 months from time of
placement was associated with a signiﬁcant decrease
in risk difference (RD6wk–6mo: 2.1%; RD6mo–24mo: 0.9%
[p ¼ 0.01]), whereas the risk difference for patients
with a BMS did not signiﬁcantly change (RD6wk–6mo:
1.9%; RD6mo–24mo: 1.0% [p ¼ 0.13]). This difference by
stent type was still observed after adjusting for
procedure characteristics during each time period
(DES: p ¼ 0.03; BMS: p ¼ 0.14).
DISCUSSION
Among patients with coronary stents, both surgical
and nonsurgical patients are at highest risk for
adverse cardiac events in the early post-stent period.
However, when examining discrete 30-day intervals
post-surgery, a higher rate of composite cardiac
events, MI, and all-cause mortality was observed for
the surgical cohort. The incremental risk of surgery
was greatest when surgery occurred in the ﬁrst 6
weeks following stent deployment and decreased to
approximately 1% after 6 months, where it remained
stable out to 24 months. Procedure characteristics
associated with signiﬁcant reduction in incremental
risk after 6 months post-stent included elective,
inpatient procedures, and in the setting of a DES.
Previous large cohort studies have reported that
rates of postoperative adverse cardiac events are
elevated in the ﬁrst 6 months following coronary
stent placement (2,4,8). In the discrete 30-day
post-stent time intervals, we observed that approxi-
mately 50% of the risk of adverse cardiac events
was due to underlying cardiac risk factors and
approximately 50% was due to surgical factors. When
FIGURE 2 Outcomes and Risk Differences in Surgical Versus Nonsurgical Cohorts
6 Months
1 Year
0%
2%
4%
6%
8%
10%
12%
Time of Matched Surgery, Days
6 Months
1 Year
0%
1%
2%
3%
4%
5%
Time of Matched Surgery, Days
Ri
sk
 D
iff
er
en
ce
 (%
) 
6 Months
1 Year
0%
2%
4%
6%
8%
10%
12%
Time of Matched Surgery, Days
6 Months
1 Year
0%
1%
2%
3%
4%
5%
Time of Matched Surgery, Days
Ri
sk
 D
iff
er
en
ce
 (%
) 
6 Months
1 Year
0%
2%
4%
6%
8%
10%
12%
0 60 12
0
18
0
24
0
30
0
36
0
42
0
48
0
54
0
60
0
66
0
72
0
0 60 12
0
18
0
24
0
30
0
36
0
42
0
48
0
54
0
60
0
66
0
72
0 0 60 12
0
18
0
24
0
30
0
36
0
42
0
48
0
54
0
60
0
66
0
72
0 0 60 12
0
18
0
24
0
30
0
36
0
42
0
48
0
54
0
60
0
66
0
72
0
0 60 12
0
18
0
24
0
30
0
36
0
42
0
48
0
54
0
60
0
66
0
72
00 60 12
0
18
0
24
0
30
0
36
0
42
0
48
0
54
0
60
0
66
0
72
0
Time of Matched Surgery, Days
 C
om
po
sit
e 
Ca
rd
ia
c 
(%
)
6 Months
1 Year
0%
1%
2%
3%
4%
5%
Time of Matched Surgery, Days
Ri
sk
 D
iff
er
en
ce
 (%
) 
Stent+Surgery
No Surgery
Stent+Surgery
No Surgery
Stent+Surgery
No Surgery
A Overall Drug-Eluting Stents Bare Metal Stents
B
 C
om
po
sit
e 
Ca
rd
ia
c 
(%
)
 C
om
po
sit
e 
Ca
rd
ia
c 
(%
)
Smoothed 30-day plot of (A) and risk differences (adjusted for procedure type, admission status, and work [relative value unit as a measure of surgical complexity]) in
(B) rates of the composite cardiac endpoint (myocardial infarction and/or revascularization) over the 24 months from the time of coronary stent placement. Gray areas
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2735surgery occurred 6 months after stenting, there was a
signiﬁcant reduction in the incremental risk of sur-
gery for: 1) elective inpatient surgery; 2) complex
procedures (as determined by higher work RVU);TABLE 4 Adverse Cardiac Events and All-Cause Mortality and Risk D
Matched Nonsurgery Cohort During the Matched 30-Day Interval, Stra
Event
<6 Weeks
(n ¼ 3222)
Event, %
Risk Difference, %
(95% CI)* Event
Composite cardiac* 9.0 2.8 (0.8 to 4.8) 4.6
MI 7.5 3.6 (1.8 to 5.4) 3.8
Revascularization 2.7 –0.1 (–1.3 to 1.1) 1.5
All-cause mortality 3.2 2.5 (1.4 to 3.6) 2.1
Risk difference reﬂects difference between the surgical cohort and the matched nons
revascularization with coronary artery bypass grafting or coronary stent placement.
MI ¼ postoperative acute myocardial infarction.and 3) high-risk cases as deﬁned by RCRI. When
appropriate, these circumstances may beneﬁt most
from delay until at least 6 months following stent,
whereas minor outpatient procedures wereifferences in the Post-Stent Cohort Undergoing Surgery Versus the
tiﬁed by Time From Coronary Stent Placement
6 Weeks to 6 Months
(n ¼ 13,419)
>6 Months to 24 Months
(n ¼ 45,129)
, %
Risk Difference, %
(95% CI)* Event, %
Risk Difference, %
(95% CI)*
2.0 (1.3 to 2.7) 2.3 0.9 (0.7 to 1.2)
2.2 (1.6 to 2.8) 1.8 1.0 (0.8 to 1.3)
0.0 (–0.5 to 0.4) 0.8 0.0 (–0.1 to 0.3)
1.4 (0.9 to 1.9) 1.1 0.8 (0.7 to 1.0)
urgical cohort following coronary stent placement. *Postoperative acute MI and/or
TABLE 5 DRD for Adverse Cardiac Events in the Stent/Surgery Group, by Surgery Characteristic, When Surgery was Performed
>6 Weeks After Stent Placement
Surgery Characteristic
6 Weeks to 6 Months
(n ¼ 13,419)
>6 Months to 24 Months
(n ¼ 45,129)
DRD p ValueEvent, %
Risk Difference, %
(95% CI) Event, %
Risk Difference, %
(95% CI)*
Overall 4.6 2.0 (1.3 to 2.7) 2.3 0.9 (0.7 to 1.2)
Stent
DES 4.3 2.1 (1.2 to 3.1) 2.1 0.9 (0.5 to 1.2) 1.3 0.01
BMS 4.9 1.9 (0.9 to 2.9) 2.4 1.0 (0.6 to 1.4) 0.8 0.13
Surgery type
Other* 7.8 5.8 (–0.5 to 12.2) 4.7 3.9 (0.8 to 7.1) 1.9 0.61
Digestive 7.0 4.6 (2.2 to 7.0) 2.1 0.9 (0.1 to 1.6) 3.7 0.003
Vascular 6.5 3.8 (1.7 to 6.0) 4.5 2.7 (1.4 to 4.0) 1.1 0.36
Respiratory 6.1 3.0 (–0.1 to 6.2) 4.7 3.3 (1.7 to 5.0) –0.3 0.84
Genital/urinary 5.1 2.0 (0.2 to 3.8) 1.8 0.8 (0.2 to 1.4) 1.2 0.19
Musculoskeletal 4.7 2.8 (0.9 to 4.8) 2.1 0.7 (0.0 to 1.3) 2.1 0.04
Nervous 3.0 0.7 (–2.0 to 3.5) 2.7 1.4 (0.3 to 2.5) –0.6 0.68
Integumentary 2.6 –0.2 (–1.6 to 1.2) 1.8 0.5 (0.1 to 1.1) –0.7 0.36
Eye/ear 2.4 –0.2 (–2.0 to 1.2) 1.3 –0.2 (0.7 to 0.4) –0.1 0.96
Admission status
Outpatient 2.9 0.1 (–0.6 to 0.9) 1.5 0.2 (0.1 to 0.5) –0.1 0.89
Elective inpatient 6.1 3.7 (2.4 to 5.0) 3.3 1.9 (1.4 to 2.5) 1.8 0.01
Nonelective inpatient† 14.9 12.3 (7.1 to 17.5) 9.2 7.6 (4.7 to 10.5) 4.7 0.12
High risk?
Yes 8.6 6.5 (4.0 to 9.0) 2.1 2.8 (1.7 to 4.0) 3.7 0.01
No 4.0 1.4 (0.7 to 2.1) 4.2 0.7 (0.5 to 1.0) 0.6 0.11
Surgical complexity
<10 RVU 4.1 1.3 (0.4 to 2.2) 2.1 0.8 (0.4 to 1.1) 0.5 0.26
10–20 RVU 4.3 1.9 (0.7 to 3.1) 2.2 0.8 (0.3 to 1.3) 1.1 0.09
>20 RVU 7.5 5.3 (2.9 to 7.7) 3.8 2.4 (1.3 to 3.5) 2.9 0.02
Risk differences reﬂect difference between the surgical cohort and the matched nonsurgical cohort following coronary stent placement. p Values reﬂect the signiﬁcance of the
change in risk difference. *Includes primary CPT codes of General (1000–10039), Hemic and Lymphatic (38100–39999), and Endocrine (60000–60999) operations. †Indicates
admission status from a source other than home.
DRD¼ change in risk difference between the time intervals of 6 weeks to 6 months and 6 months to 24 months following coronary stent placement; other abbreviations as in
Tables 1 and 2.
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2736associated with insigniﬁcant incremental risk (Central
Illustration). Furthermore, although the incremental
risk decreased for both BMS and DES, the change was
signiﬁcant only for DES when surgery was more than
6 months after stent placement. Underlying patient
conditions inherent to decision-making for BMS
placement, not necessarily stent characteristics,
likely explain this. These results further reﬁne the
incremental risk of noncardiac surgery in patients
with coronary stents and how the risk is modulated
over time.
Speciﬁc risk factors associated with adverse cardiac
events after coronary stent placement include age,
diabetes, renal failure, congestive heart failure, and
recent MI (13–17). These comorbid conditions are
important components of the RCRI and used to
predict the risk of adverse perioperative cardiac
events in patients with coronary artery disease (9).
After matching these cardiac risk factors, we foundno signiﬁcant difference in cumulative incidence of
adverse cardiac event rates between the surgical
population and their nonsurgical matches over the 24
months following stenting. However, mortality rates
were signiﬁcantly higher in the surgical population
compared to the nonsurgical population. The similar
rate of cardiac events during this time period among
both cohorts implies that the difference in mortality
is largely accounted for by noncardiac causes of
death in the surgical population. The observed
increased mortality risk among surgical patients
likely reﬂects the underlying disease processes
necessitating a surgery and other noncardiac post-
operative complications (18).
Previous studies of post-operative adverse cardiac
events have reported similar rates, on the basis of
stent type with elevated rates for patients with BMS
(2,19,20). A limitation of these observational studies
is confounded by indication for stent selection that
CENTRAL ILLUSTRATION Risk Difference in Adverse Cardiac Events in the 30 Days Following Surgery for
Patients With Coronary Stents
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Procedure*
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4.0%
5.0%
6.0%
Outpatient
Procedure
Complex Procedure
(RVU>20)*
Any Procedure
in Patients With a DES*
Time from coronary stent placement:
 Holcomb, C.N. et al. J Am Coll Cardiol. 2014; 64(25):2730–9.
Risk difference for adverse cardiac events (myocardial infarction and/or revascularization) in the 30 days following surgery for the surgical
cohort by time from coronary stent placement. The referent group is the nonsurgical cohort. *Indicates the change in risk difference is sta-
tistically signiﬁcant at p < 0.05. DES ¼ drug-eluting stent(s); RVU ¼ relative value unit(s).
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2737cannot be adequately controlled in a surgical cohort.
In this analysis, we compared the incremental risk of
surgery to nonsurgical control subjects matched by
stent type. When examining incremental risk by stent
type, we found that: 1) the overall adverse event rates
were lower in patients with a DES regardless of
whether they underwent surgery; 2) the incremental
risk of surgery was similar for both stent types in the
ﬁrst 6 months; and 3) the incremental risk of surgery
was signiﬁcantly reduced when surgery occurred
more than 6 months following stent placement in
patients with DES, but not BMS. These observations
provide further evidence that the higher rates of post-
surgical adverse cardiac events in patients with BMS
are more likely due to the underlying patient condi-
tions that led to BMS selection than the interaction
with stent type and surgery. Additionally, these data
provide further reassurance that the incremental risk
of surgery in patients with DES is minimal, especially
when surgery occurred more than 6 months after
stenting. The current guidelines for the timing of
noncardiac surgery following stent are dictated by
stent type. These ﬁndings and our previous work (4)
suggest that focus should be shifted away from
stent type and toward a patient’s cardiac and surgicalrisk factors when considering the optimal timing of
surgery following coronary stent placement.
STUDY LIMITATIONS. Several considerations need to
be applied to our ﬁndings. First, the study sample is
comprised primarily of older male patients, thus
limiting the generalizability to women or younger
men. Second, surgical procedures were distributed
over a broad range of procedures, and although this
increases generalizability, the overall ﬁndings may
not apply equally to every subpopulation in this
study. Third, patients were matched on the basis of
clinical criteria and stent type, but we were not able
to include important variables such as the number
and length of stents placed at the time of cardiac
catheterization (21). Although we did have informa-
tion on whether stents were placed for acute versus
nonacute coronary syndromes, a selection bias does
exist for whether patients were chosen to receive BMS
or DES. This is evident in our analysis, demonstrating
that both the surgical and nonsurgical cohorts with
BMS had higher overall adverse cardiac events over
the study period. We also did not have information
on cardiac function, limiting our ability to further
discern important cardiac determinants of adverse
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Patients with coronary stents undergoing noncardiac
surgery are at an increased risk for adverse cardiac
events, especially during the ﬁrst 6 months after stent
placement.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to provide more granular information
about outcomes associated with noncardiac surgery in
relation to patient demographics, the number and
types of stents deployed, and alternative periopera-
tive strategies for managing antithrombotic therapy.
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2738postoperative events. These speciﬁc limitations mean
that unmeasured confounding could explain timing
from coronary stent and adverse cardiac events.
Fourth, we relied on administrative data to determine
our endpoints, which could result in misclassiﬁcation
bias. Fifth, we did not measure the effects of anti-
platelet management, including duration or in-
terruptions in therapy. Thus, we cannot infer what
association, if any, antiplatelet therapy had on
adverse cardiac events over the study period. How-
ever, our prior study and others did not ﬁnd an asso-
ciation between temporary antiplatelet therapy
cessation and major adverse cardiac events (4,22,23).
Finally, a selection bias exists as we included in the
analysis only patients who survived until the time of
surgery in both the study and control groups to be able
to directly compare 30-day postoperative outcomes.
This bias may render lower estimated risks than exists
in the entire population with coronary stents.
CONCLUSIONS
The incremental risk of noncardiac surgery on
adverse cardiac events in patients with coronary
stents is related to timing of surgery following stent
with the highest risk early post-stent placement and
stabilizes by approximately 1%, 6 months after
stenting. Elective major inpatient procedures espe-
cially in patients with DES were associated with sig-
niﬁcant reductions in the incremental risk when
performed more than 6 months following coronarystent. Accordingly, these surgeries may beneﬁt most
from delay beyond 6 months.
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